Robert Way
- AstraZeneca (AZN) said its perioperative Imfinzi combined with enfortumab vedotin demonstrated statistically significant improvements in event-free and overall survival compared with standard of care in patients with muscle-invasive bladder cancer, according to a statement.
- Patients in the comparator arm had
